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Introduction
Coronary arterial thrombosis is a complex pathologic cas-
cade involving diseased endothelium, exposure of suben-
dothelial matrix, platelet activation, platelet aggregation,
and generation of thrombin ultimately leading to assembly
of a shear resistant platelet–fibrin thrombus. The contribu-
tions of both platelets and fibrin to mechanical properties of
clot formation have been well studied.1,2
Increasing interest has focused on the ability to persona-
lizemedical therapy across all subspecialties including those
focusing on treatment of cardiovascular disease.3,4 Clinical
trials have started to focus on treating particular subgroups
of patients with coronary artery disease in secondary pre-
vention, such as patients with multiple cardiovascular risk
factors, to isolate either high-risk subgroups or groups
expected to respond to the experimental therapy.5
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Abstract Background High plasma fibrin clot strength (MA) measured by thrombelastography
(TEG) is associated with increased risk of cardiac events after percutaneous coronary
interventions (PCIs). Factor XIIIa (FXIIIa) cross-links soluble fibrin, shortens clot
formation time (TEG-K), and increases final clot strength (MA).
Methods We analyzed platelet-poor plasma from patients with previous PCI. Kaolin-
activated TEG (R, K, MA) in citrate platelet-poor plasma and FXIIIa were measured
(n ¼ 257). Combined primary endpoint was defined as recurrent myocardial infarction
(MI) or cardiovascular death (CVD). Relationship of FXIIIa and TEG measurements on
cardiac risk was explored.
Results FXIIIa correlated with TEG-MA (p ¼ 0.002) and inversely with TEG-K
(p < 0.001). High MA (35.35 mm; p ¼ 0.001), low K (<1.15 min; p ¼ 0.038), and
elevated FXIIIa (83.51%; p ¼ 0.011) were associated with increased risk of CVD or MI.
Inclusion of FXIIIa activity and low TEG-K in risk scores did not improve risk prediction as
compared with high TEG-MA alone.
Conclusion FXIIIa is associated with higher plasma TEG-MA and low TEG-K. High FXIIIa
activity is associated with a modest increase in cardiovascular risk after PCI, but is less
sensitive and specific than TEG-MA. Addition of FXIIIa does not provide additional risk
stratification beyond risk associated with high fibrin clot strength phenotypemeasured
by TEG.
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Thrombelastography (TEG) is an ex vivo thrombosis assay
that is able to measure the kinetics of clot formation.6,7 High
clot strengthmeasured by TEG has been found to be amarker
associated with increased thrombotic risk in various clinical
circumstances.8,9 We recently described our findings of an
association with elevated plasma fibrin clot strength mea-
sured by TEG and increased risk of future recurrent myo-
cardial infarction (MI) and stent thrombosis in a cohort of
patients with coronary artery disease and percutaneous
coronary intervention (PCI).10
Factor XIII (FXIII) is activated by thrombin and as the final
enzymatic step in the coagulation cascade, it cross-links
assembled soluble fibrin strands into a solid, shear resistant
fibrin network.2,11–13 In addition to cross-linking of fibrin
strands, FXIIIa also has other anti-fibrinolytic functions, and
participates in platelet-mediated clot contraction.13,14 Defi-
ciency of FXIII causes severe bleeding diathesis and restitu-
tion of FXIII in FXIII-deficient plasma dose-dependently
increases clot strength measured by TEG.11 The contribution
of FXIIIa activity to the risk of recurrent coronary thrombosis
in patients treated with dual-antiplatelet therapy has not
been previously studied.
We intended to further investigate the relative contribu-
tion of factor FXIIIa activity on ischemic risk, as well as
interaction of FXIIIa with other TEG parameters (MA: max-
imal clot strength; R: reaction time; K: clot formation time)
in the previously published cohort.10
Methods
Study Design and Patient Population
The study protocol was approved by the Indiana University
Institutional Review Board. All subjects provided written
informed consent. We enrolled subjects among patients
referred for cardiac catheterization or in follow-up to a
cardiac catheterization. Subjects were included in this ana-
lysis if they had angiographically established coronary artery
disease and had undergone PCI. In addition, to be included in
this analysis, all subjects had to have had both plasma TEG
and FXIIIa measurements completed.
Blood Samples
Blood samples were collected into Vacutainer tubes contain-
ing Na-citrate 3.2%. Whole citrate blood was centrifuged at
2,000  g for 15 minutes and resulting platelet-poor citrate
plasma was stored at 80°C until analysis. Blood samples
were obtained prior to or at least 12 hours after administra-
tion of heparin or bivalirudin.
Thrombelastography
We performed kaolin-activated TEG in citrate platelet-poor
plasma according to the manufacturer’s instructions
(TEG5000 system, Haemonetics, Braintree, Massachusetts,
United States). Citrate plasmawasmixedwith kaolin, inverted
five times, and then loaded in a heparinase-coated cup con-
taining 20 µL of CaCl2. TEG was stopped after maximal fibrin
clot strength was recorded. Time to fibrin formation or
reaction time (R, min), clot formation time (defined as time
frombeginningofclot formationuntil clotfirmness amplitude
reaches 20 mm;K,min), andmaximal clot strength (MA,mm)
were recorded.
Factor XIIIa
Factor XIIIa concentration (FXIII–subunit A) was measured
by enzyme-linked immunoassay in citrate plasma according
to themanufacturer’s instructions (FXIIIa [human] ELISA kit;
Aniara, West Chester, Ohio, United States). In the assay, the
FXIIIa concentration is expressed as percentage, standar-
dized to a normal human-citrated plasma pool. The average
normal concentration of FXIII tetramer in plasma is 25 μg/
mL according to the manufacturer of the assay (Aniara).
Clinical Endpoints
The primary combined endpoint was defined as first occur-
rence of cardiovascular death (CVD) or MI. Myocardial infarc-
tionwas defined according to the universal definition of MI.15
Secondary endpoints included CVD,MI, stent thrombosis, and
bleeding. Stent thrombosis was defined as definite, probable,
and possible, based on the Academic Research Consortium’s
definition of stent thrombosis.16 Bleeding was recorded if
severe or life-threatening as defined by GUSTO criteria.17 We
evaluated clinical endpoints through review of electronic
medical records, and last clinical follow-up was used as last
censored time event. If available, coronary angiograms were
reviewed to ascertain stent thrombotic events.
Statistics
We employed SPSS 23.0 (IBM, United States) for statistical
analysis. Significance was defined as p < 0.05 and all tests
were conducted two-sided, with values represented asmean
 SD except as otherwise stated. Continuous normally dis-
tributed data were compared with unpaired Student’s t-test,
and categorical variables were compared using the χ2 test.
Survival analysis was performed using Kaplan–Meier
method. We conducted multivariate Cox regression analysis
for clinical endpoints with highMA, highMA/lowK, and high
FXIIIa, with forward conditional adjustment for baseline
clinical variables.
Results
A total of 257 subjects were included in the analysis. The
mean age of patients was 57.2  10 years. The clinical
variables of subjects included in the analysis are summarized
in ►Table 1. Mean time of follow-up was 2.9 years. The
primary endpoint of CVD and MI occurred in 14.4% and
definite stent thrombosis in 3% of subjects.
Factor XIIIa concentration correlated with TEG-MA (ρ ¼
0.191; p ¼ 0.002) and inversely with TEG-K (ρ ¼ 0.251;
p < 0.001), but not TEG-R (►Fig. 1). Clot formation time
(TEG-K) was correlated with time to clot formation (TEG-R;
ρ¼ 0.61; p < 0.001), and inverselywith clot strength (TEG-MA)
(ρ ¼ 0.31; p < 0.001). Scatterplot demonstrates clustering
of recurrent ischemic events in cases with high TEG-MA, low
TEG-K, and elevated FXIIIa (►Fig. 1). Maximal clot strengthwas
significantly higher in subjects with occurrence of the primary
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endpoint during follow-up (recurrent CVD or MI; TEG-MA:
39.6  7.7 vs. 35.4  7.5 mm; p ¼ 0.002) and clot formation
time was shorter (TEG-K: 1.15  0.5 vs. 1.54  1.3 minutes;
p ¼ 0.002; ►Fig. 1), as previously published. Patients with
definite stent thrombosis during follow-up had significantly
higher fibrin MA than subjects without definite stent thrombo-
sis (TEG-MA: 41.6  9 vs. 35.8  8 mm; p ¼ 0.048). Patients
with possible, probable, or definite stent thrombosis during
follow-up demonstrated significantly higher MA than
subjects without stent thrombosis (TEG-MA: 44.1  10 vs.
Table 1 Baseline demographics and clinical variables for total study population, and grouped according to low and high FXIIIa
Variables Total
(n ¼ 257)
Low FXIIIa
(<83.51%)
(n ¼ 116)
High FXIIIa
(83.51%)
(n ¼ 141)
p-Value
Age (y) 57.2  9.9 59.3  10 55.4  9 0.001
BMI (kg/m2) 31.7  6.9 30.8  6.6 32.3  7.1 0.083
Male gender (%) 152/257 (59%) 63/116 (54%) 89/141 (59%) 0.15
African American (%) 61/257 (24%) 22/116 (19%) 39/141 (28%) 0.1
Smoking (%) 97/257 (38%) 43/116 (37%) 54/141 (38%) 0.84
Hypertension (%) 237/257 (92%) 108/116 (93%) 129/141 (92%) 0.63
Hyperlipidemia (%) 231/257 (90%) 108/116 (93%) 123/141 (87%) 0.12
Diabetes mellitus (%) 111/257 (43%) 53/116 (46%) 58/141 (41%) 0.46
History of myocardial infarction 168/257 (65%) 72/116 (62%) 96/141 (68%) 0.31
History of CABG 51/257 (20%) 25/116 (22%) 26/141 (18%) 0.53
Congestive heart failure (%) 41/257 (16%) 18/116 (16%) 23/141 (16%) 0.86
Clinical presentation
STEMI 37/257 (14%) 11/116 (10%) 26/141 (18%) 0.042
NSTEMI 56/257 (22%) 20/116 (17%) 36/141 (26%) 0.11
Unstable angina 65/257 (25%) 34/116 (29%) 31/141 (22%) 0.18
Stable CAD 95/257 (37%) 51/116 (44%) 44/141 (31%) 0.035
PCI vessel
Left main 3/257 (1%) 1/116 (1%) 2/141 (1%) 0.68
LAD 109/257 (42%) 50/116 (43%) 59/141 (42%) 0.84
CX 64/257 (25%) 26/116 (22%) 38/141 (27%) 0.4
RCA 113/257 (44%) 47/116 (41%) 66/141 (47%) 0.31
Number of stents implanted 1.52  0.8 1.44  0.8 1.59  0.8 0.16
Drug eluting stents 192/257 (75%) 86/116 (74%) 106/141 (75%) 0.85
Paclitaxel eluting stent 41/257 (16%) 23/116 (20%) 18/141 (13%) 0.12
Sirolimus eluting stent 14/257 (5%) 5/116 (4%) 9/141 (6%) 0.47
Zotarolimus eluting stent 8/257 (3%) 2/116 (2%) 6/141 (4%) 0.25
Everolimus eluting stent 127/257 (49%) 53/116 (46%) 74/141 (53%) 0.28
Beta-blockers (%) 236/257 (92%) 110/116 (95%) 126/141 (89%) 0.11
ACE-inhibitors/ARB (%) 185/257 (71%) 78/116 (67%) 104/141 (74%) 0.25
Calcium channel blockers (%) 38/257 (15%) 21/116 (18%) 17/141 (12%) 0.17
Statins 226/257 (88%) 101/116 (87%) 125/141 (89%) 0.7
Aspirin 256/257 (99.6%) 115/116 (99%) 141/141 (100%) 0.27
Clopidogrel 210/257 (82%) 101/116 (87%) 109/141 (77%) 0.044
Prasugrel 34/257 (13%) 9/116 (8%) 25/141 (18%) 0.02
Ticagrelor 7/257 (3%) 2/116 (2%) 5/141 (4%) 0.37
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CABG, coronary artery bypass grafting; CAD,
coronary artery disease; CX, circumflex; BMI, body mass index; LAD, left anterior descending; NSTEMI, non-ST-elevation myocardial infarction;
PCI, percutaneous coronary intervention; STEMI, ST-elevation myocardial infarction.
Note: Comparison of variables with t-test for continuous variables and chi-square for categorical variables.
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35.7  7 mm; p ¼ 0.001). Time to clot formation (R) was
not significantly different for subjects with primary endpoint
(TEG-R: 6.6  3 vs. 7  2.9minutes; p ¼ 0.38) or definite stent
thrombosis (TEG-R: 5.9  2 vs. 7  3 minutes; p ¼ 0.37) as
compared with those without events.
Optimal cutoff for high fibrin clot strength (MA
 35.35 mm) was determined by receiver operating curve
(ROC) analysis for the primary endpoint (area under curve
[AUC] ¼ 0.652, p ¼ 0.002), as previously published.10 To
assess the added prognostic value of FXIIIa to TEG-MA
measurements, we divided the study group into subjects
with either low or high FXIIIa, with cutoff (<83.51%) derived
from ROC analysis (AUC: 0.572, p ¼ 0.164; ►Table 1). Simi-
larly, we determined the cutoff for low TEG-K (K < 1.15 min,
AUC: 0.6; p ¼ 0.06) for inclusion in risk prediction score.
Subjects with high FXIIIa (89.51%) were younger, had
more often presented with STEMI, and were more likely to
have been treated with prasugrel (►Table 1). Subjects with
high FXIIIa showed shorter clot formation times (TEG-K) and
higher maximal clot strength (TEG-MA), but no significant
difference in time to clot formation (TEG-R; ►Table 2).
Survival free analysis by Kaplan–Meier demonstrated sig-
nificantly increased risk for theprimary combined endpoint of
CVD and MI, as well as MI and stent thrombosis (►Fig. 2) in
subjects with high clot strength (MA; ►Fig. 2), as previously
reported. Short clot formation time (K) and high FXIIIa were
both associated with significantly increased risk of CVD and
MI, and MI alone, but not stent thrombosis (►Fig. 2).
Cox regression analysis was performed with forward con-
ditional adjustment for baseline clinical variables. Both unad-
justedand adjustedhazard ratios and95%confidence intervals
for individual clinical endpoints are provided in ►Table 3 for
high versus low MA. High MA remained associated with
increased hazard for the occurrence of CVD or MI, CVD, and
MI after adjustment inmultivariate analysis (►Table 3). There
was a nonsignificant trend toward increased bleeding events
in subjects with low MA (►Table 3).
The combination of low TEG-K with high TEG-MA was
associated with increased risk of occurrence of the primary
endpoint (►Figs. 1 and 2), and therefore a “TEG risk score”
was explored that would focus on a more select group of
Fig. 1 Scatterplot of thrombelastography (TEG) and FXIIIa measures in subjects without events (blue) and subjects with cardiovascular death or
MI (red). FXIIIa, factor XIIIa; TEG-K, clot formation time; TEG-MA, maximal fibrin clot strength; TEG-R, time to fibrin formation.
Table 2 Plasma TEG measures stratified by low and high FXIIIa
Low FXIIIa
(<83.51%)
High FXIIIa
(83.51%)
p-Value
TEG-R (min) 7.1  2.7 6.8  3.1 0.33
TEG-K (min) 1.6  1.3 1.3  1.1 0.041
TEG-MA (mm) 34.3  7.8 37.4  7.2 0.001
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Fig. 2 Kaplan–Meier survival analysis according to high (35.35 mm) versus low TEG-MA (<35.35 mm) (A–C), high (1.15 min) versus low TEG-K
(>1.15min) (D–F), and high (83.51%) versus low FXIIIa (<83.51%) (G–I) for primary endpoints of CVD orMI, MI (C), and possible/probable/definite stent
thrombosis.
Table 3 Unadjusted and adjusted hazard ratio for clinical outcomes associated with high and low TEGMA in Cox regression analysis
Clinical events Low MA
(<35.35 mm)
(n ¼ 122)
High MA
(35.35 mm)
(n ¼ 135)
Unadjusted
hazard ratio
(95% CI)
p-Value Adjusted
hazard ratio
(95% CI)
p-Value
Cardiovascular death or
myocardial infarction
8/122 (6.6%) 28/135 (20.7%) 3.5 (1.6–7.8) 0.002 3.39 (1.5–7.2) 0.003
Cardiovascular death 0/122 (0%) 8/135 (5.8%) 64.2 (0.2–18984) 0.15 64.2 (0.2–18984) 0.15
Myocardial infarction 8/122 (6.6%) 24/135 (17.8%) 3.05 (1.4–6.8) 0.006 2.74 (1.1–6.3) 0.017
Definite, probable,
or possible
stent thrombosis
1/122 (0.8%) 8/135 (5.9%) 7.7 (0.96–61.3) 0.055 5.2 (0.64–42.1) 0.12
Bleeding 6/122 (4.9%) 2/135 (1.5%) 0.32 (0.07–1.6) 0.17 0.23 (0.04–1.3) 0.09
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subjects at risk who exhibited both high MA and low K. Both
unadjusted and adjusted hazard ratios for high TEG risk score
were significant for occurrence of CVD/MI, MI, and probable,
possible, and definite stent thrombosis (►Table 4). Next the
risk associated with high FXIIIa was analyzed and increased
hazard was observed for occurrence of CVD and MI, and MI
alone, that remained significant after adjustment in multi-
variate analysis (►Table 5). High FXIIIa was associated with
more frequent bleeding events, although this difference was
not statistically significant (►Table 5). Next the integration
of high MA, low K, and high FXIII into a combined TEG/FXIII
risk score was explored. The presence of at least two of three
risk variables (high MA, low K, and high FXIIIa) was asso-
ciatedwith increased risk for CVD andMI,MI alone, and stent
thrombosis after multivariate adjustment (►Table 6). Sensi-
tivity and specificity of each risk score are summarized
Table 4 Unadjusted and adjusted hazard ratio for clinical outcomes associated with presence of combination of high MA and low K
in Cox regression analysis
Clinical events Low TEG risk score
(either MA < 35.35
or K  1.15 min)
(n ¼ 171)
High TEG risk score
(MA  35.35 mm
and K < 1.15 min)
(n ¼ 86)
Unadjusted
hazard ratio
(95% CI)
p-Value Adjusted
hazard ratio
(95% CI)
p-Value
Cardiovascular death
or myocardial
infarction
16/171 (9.4%) 20/86 (23.3%) 3.53 (1.8–6.9) 0.0002 3.48 (1.75–6.9) 0.0004
Cardiovascular death 4/171 (2.3%) 4/86 (4.7%) 2.8 (0.68–11.8) 0.15 3.3 (0.8–13.7) 0.1
Myocardial infarction 14/171 (8.2%) 18/86 (20.9%) 3.7 (1.8–7.5) 0.0004 3.56 (1.72–7.4) 0.001
Definite, probable,
or possible
stent thrombosis
3/171 (1.8%) 6/86 (7%) 6.1 (1.45 -25.3) 0.013 6.2 (1.58–24.2) 0.036
Bleeding 7/171 (5.1%) 1/86 (1.2%) 0.39 (0.05–3.2) 0.38 0.19 (0.02–2) 0.17
Table 5 Unadjusted and adjusted hazard ratio for clinical outcomes associated with high and low FXIIIa in Cox regression analysis
Clinical events Low FXIIIa
(<83.51)
(n ¼ 116)
High FXIIIa
(83.51%)
(n ¼ 141)
Unadjusted
hazard ratio
(95% CI)
p-Value Adjusted
hazard ratio
(95% CI)
p-Value
Cardiovascular death or
myocardial infarction
10/116 (8.6%) 26/141 (18.4%) 2.5 (1.2–5.2) 0.014 2.39 (1.14–5) 0.022
Cardiovascular death 2/116 (1.7%) 6/141 (4.3%) 2.89 (0.58–14.4) 0.2 3.29 (0.58–18.7) 0.18
Myocardial infarction 8/116 (6.9%) 24/141 (17%) 2.88 (1.29–6.4) 0.01 3.04 (1.3 -7.1) 0.01
Definite, probable,
or possible
stent thrombosis
3/116 (2.6%) 6/141 (4.3%) 1.9 (0.47 -7.6) 0.37 1.56 (0.34 -7.2) 0.57
Bleeding 1/116 (0.9%) 7/141 (5%) 7.5 (0.9–61) 0.06 7.2 (0.87–59.1) 0.07
Table 6 Unadjusted and adjusted hazard ratio for clinical outcomes associated with high (>1) and low (1) TEG and FXIIIa risk
score in Cox regression analysis
Clinical events Low combined
TEG/FXIIIa risk
score (0–1)
(n ¼ 110)
High combined
TEG/FXIIIa risk
score (2–3)
(n ¼ 145)
Unadjusted
hazard ratio
(95% CI)
p-Value Adjusted
hazard ratio
(95% CI)
p-Value
Cardiovascular death
or myocardial infarction
8/110 (7.3%) 28/145 (19.3%) 3.45 (1.56–7.6) 0.002 3.6 (1.61–8) 0.002
Cardiovascular death 1/110 (0.9%) 7/145 (4.8%) 7.3 (0.88–60) 0.065 7.2 (0.86–59) 0.069
Myocardial infarction 7/110 (6.4%) 25/145 (17.2%) 3.6 (1.5–8.36) 0.003 3.73 (1.54–9) 0.004
Definite, probable,
or possible stent
thrombosis
1/110 (0.9%) 8/145 (5.5%) 8.1 (1.0 -65.1) 0.05 9.7 (1.08 -87.2) 0.043
Bleeding 5/110 (4.5%) 3/145 (2.1%) 0.61 (0.14–2.59) 0.5 0.38 (0.07–2) 0.26
Note: TEG risk score (number of categories present: TEG-MA  35.35 mm; TEG-K < 1.15 min; FXIIIa  83.51%).
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in ►Table 7. Addition of low K, high FXIII, individually or in
combined risk score, did not significantly improve sensitivity
and specificity as compared with use of high TEG-MA alone
with lower AUC values for endpoints listed (►Table 7).
Discussion
The results of our study demonstrate that patients who form
mechanically shear resistant, high strength plasma fibrin clot
(highMA) with short clot formation time (low K) appear to be
at risk for recurrent thrombotic events after coronary stenting,
in specific CVD and MI, as well as stent thrombosis. We
demonstrate a correlation between these parameters to a
certain extent, particularly MA, K, and R. In addition, FXIIIa
levels correlate with final maximal plasma fibrin clot strength
and inversely with clot formation time, as previously demon-
strated for whole blood and plasma TEG measurements in
normal control populations.2,11 Our exploratory analysis
demonstrates that high FXIIIa was associated with modest
increase in risk of recurrent CVD and MI, but not stent
thrombosis. Inclusion of TEG-K and FXIIIa into exploratory
risk scores did not further increase the performance of high
plasma fibrin TEG-MA as predictor of recurrent thrombotic
events after coronary stenting. While high clot strength (MA)
inwhole blood has been accepted as a risk variable for arterial
thrombosis, there has been less awareness of clot formation
time (K) as additional parameter of clot kinetics in prognostic
risk, and our findings of ischemic risk associated with this
parameter are noteworthy.9,18–22 In particular, rapid clot
formation is dependent on rapid generation of thrombin as
well as fibrin generation and cross-linking, both parameters
that can be altered by treatment with anticoagulants.23 In
addition, anticoagulants such as heparin or factor Xa antago-
nists loosen clot structure, rendering it more susceptible to
fibrinolysis.20 This may be important, since the recent “Cardi-
ovascular Outcomes for People Using Anticoagulation Strate-
gies” (COMPASS) trial demonstrated superiority of combined
treatment with low-dose rivaroxaban and aspirin over aspirin
alone in the prevention of recurrent events in patients with
stable CAD.5 The combination of rivaroxaban 2.5 mg twice
daily and aspirin 100 mg daily demonstrated a reduction in
combined cardiovascular ischemic endpoints, and also overall
mortality as compared with aspirin alone.5 The protection
from ischemic events in COMPASS came at the cost of a mild
increase in bleeding events, whichmay limit the broad applic-
abilityofcombinedaspirin and rivaroxaban inclinical practice.
Thus, an ex vivo assay thatmay identify subjectswith evidence
of procoagulant tendency, such as low K and high MA, may
possibly be able to identify patients who most benefit from
treatment with anticoagulants.
The results of our study suggest that FXIIIa contributes at
least in part to high clot strength phenotype, and may in part
contribute to risk of subsequent coronary thrombotic events,
although only modestly. The importance of FXIIIa in both
venous and arterial thrombosis is increasingly recognized.13
Themajority of circulating FXIII is stored in platelets, and FXIIIa
exposed on the surface of activated platelets contributes to
stabilization of FXIII-depleted thrombi and antifibrinolytic
function.13,24,25Redblood cell retention inwholeblood throm-
bus is dependent on FXIIIa.26 Platelets from FXIII-deficient
patients exhibit decreased platelet activation and adhesion to
fibrinogen.27Wehave previously demonstrated a rise in FXIIIa
concentration in plasma supernatant occurring after platelet
aggregation, suggesting some degree of release of FXIIIa into
plasma from platelets, the mechanism of which remains
unclear.28 It is reasonable to assume that platelets activated
at the site of arterial thrombus contribute to fibrin clot stabi-
lization either by direct or indirect exposure of FXIIIa contents.
In our study,wemayhaveunderestimated theeffectof platelet-
bound FXIII by utilizing platelet-poor plasma for TEGmeasure-
ments and FXIIIa assays. The contribution of platelet-bound
FXIIIamaybedetectedwithwholeblood–basedTEGassays, but
the differential contribution of FXIIIa activity versus platelets
and fibrin is more difficult to interpret. While similar in
concept, the measurements of plasma fibrin MA in our study
arehigher thanwhat isgenerallyobserved foractivatorchannel
used in whole blood TEG platelet mapping systems. Activator
channel in whole blood TEG platelet mapping assay uses
externally added reptilase to cleave fibrinogen into fibrin in
the absence of thrombin formation which is inhibited by
Table 7 Sensitivity, specificity, PPV, NPV, and c-statistic for high TEG-MA, combination of high TEG-MA/low TEG-K, and combined
TEG MA/K/FXIIIa score for CVD, MI, and possible/probable/definite ST
Score Outcome Sensitivity Specificity PPV NPV AUC p-Value
TEG (MA  35.35 mm) CVD/MI 77.8% 51.6% 20.7% 93.4% 0.647 0.005
TEG (MA  35.35 mm) MI 75% 50.7% 17.8% 93.4% 0.628 0.019
TEG (MA  35.35 mm) ST 88.9% 48.8% 5.9% 99.1% 0.688 0.055
TEG (MA  35.35 mm and K < 1.15 min) CVD/MI 55.5% 70.1% 23.3% 90.6% 0.628 0.013
TEG (MA  35.35 mm and K < 1.15 min) MI 56.3% 69.8% 20.9% 91.8% 0.63 0.017
TEG (MA  35.35 mm and K < 1.15 min) ST 66.7% 67.8% 7% 98.2% 0.672 0.08
TEG and FXIIIa score (>1) CVD/MI 78% 46.6% 19.3% 92.7% 0.624 0.017
TEG and FXIIIa score (>1) MI 78.1% 46.2% 17.2% 93.6% 0.624 0.023
TEG and FXIIIa score (>1) ST 88.9% 44.3% 5.5% 99.1% 0.668 0.087
Abbreviations: CVD, cardiovascular death; MI, myocardial infarction; NPV, negative predictive value; PPV, positive predictive value; ST, stent thrombosis.
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heparin, as well as added FXIIIa to cross-link fibrin, thus not
requiring in vivo cleaving of FXIII by thrombin into A and B
subunits. The difference in MA between the methods is con-
sistent with lower clot strength seen for same TEG assays
performed in whole blood as compared with platelet-rich
plasma, possibly due to incorporation of red cells into fibrin
network.1 Also the difference in anticoagulants in both assays
(citrate vs. heparin) and absence of thrombin in activator
channel could influence effectiveness of fibrin cross-linking
and the final result of fibrin clot strength. Due to extrinsic
addition of FXIIIa in activator channel of whole blood TEG
assays, activationofFXIIIdoesnotoccur at sitesusuallyexposed
to thrombin, such as platelets, microparticles, or red cells.
Incorporation of red cells into whole blood thrombus has
been shown to be dependent on FXIIIa adding resistance to
fibrinolysis.13,26 Differences between other functional fibrino-
genassays andplasmafibrin clot strengthmeasured inplatelet-
poor plasma have been previously reported for ROTEMassay.29
While the adjusted hazard ratios for high TEG-MA, low
TEG-K, and high FXIIIa are relatively modest, they are still
higher than relative risk observed for recurrent MACE with
high PRU measured by VerifyNow P2Y12, a now well-
accepted measure of high on treatment platelet reactivity
and risk variable after coronary stenting.30
Given the associated bleeding risk with any form of
intensified antithrombotic treatment regimens, in particular
in subjects at higher risk for bleeding in general, the utility of
an ex vivo assay that possess predictive qualities for both risk
and harm increases. This is a role that TEG as global throm-
bosis assay may be poised to accomplish.
Further investigations to assess the utility of inhibition of
FXIIIa to moderate thrombotic risk may be warranted; how-
ever, this therapeutic approach may be limited by the
increased risk of adverse bleeding as observed in patients
with inherited FXIII deficiency.31
Limitations of our study include the relative small sample
size and the relatively modest predictive values for TEG-MA,
TEG-K, and FXIIIa. Our studywas not powered to evaluate the
performance of TEG or FXIIIa activity measurements in
prediction of bleeding risk, andwe did not includefibrinogen
measurements. In addition, the contribution of FXIIIa stored
in platelets to thrombosis may have been underestimated by
use of platelet-poor plasma samples in TEG measurements.
Conclusion
High plasma fibrin clot strength (TEG-MA), short clot forma-
tion time (TEG-K), and high FXIIIa were associated with
increased risk of recurrent thrombotic events after coronary
intervention. High plasmafibrin clot strength (TEG-MA)with-
out incorporation of other parameters was superior to combi-
nation of all parameters in combined predictive risk scores.
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